Clinical Context of Stool Eosinophil Activation Protein and Anti-Gliadin Antibodies
These two stool markers—eosinophil activation protein and anti-gliadin antibodies—are not recognized as standard diagnostic tests for any gastrointestinal condition and should not guide your clinical decision-making in this patient. The current AGA guidelines for evaluating chronic diarrhea and IBS-D do not recommend either test 1, 2.
Stool Anti-Gliadin Antibodies: Poor Diagnostic Performance
Stool anti-gliadin antibodies have been studied for celiac disease screening but demonstrated unacceptably poor sensitivity and specificity. A validation study in children with celiac disease found:
- Sensitivity: 6% (0-29%)
- Specificity: 97% (89-100%)
Even when optimized, sensitivity only reached 82% at the cost of specificity dropping to 58% 3. This means the test misses 94% of celiac disease cases at recommended cut-offs—making it clinically useless.
What You Should Do Instead for Celiac Screening
The AGA strongly recommends serum IgA tissue transglutaminase (IgA-tTG) with a second test to detect celiac disease in IgA deficiency 1. This serum test has:
- Sensitivity >90%
- Specificity >90%
- Moderate-quality evidence supporting its use 2
For your patient, order serum IgA-tTG if you haven't already. The stool anti-gliadin result is unreliable and should be disregarded.
Fecal Eosinophil Activation Protein: Limited Evidence
Fecal eosinophil cationic protein (F-ECP), a marker of eosinophil activation, has been studied primarily in collagenous colitis, not in disorders of gut-brain interaction or IBS 4. In that specific context:
- 92% of active collagenous colitis patients had elevated F-ECP
- It normalized with budesonide treatment
- It showed better discrimination than calprotectin for collagenous colitis
Why This Doesn't Apply to Your Patient
Your patient has:
- Normal calprotectin (ruling out significant IBD)
- Normal secretory IgA
- Normal endoscopy and imaging
- A 4-year history consistent with a disorder of gut-brain interaction
There is no evidence that F-ECP has diagnostic utility in functional GI disorders like IBS or disorders of gut-brain interaction. The test was studied in microscopic colitis—a completely different pathophysiology involving mucosal eosinophil infiltration that your patient's normal endoscopy has already excluded.
What These Results Mean (or Don't Mean)
The elevated markers likely represent:
- False positives from tests with poor validation
- Non-specific findings without established disease correlation in functional GI disorders
- Marketing-driven testing from commercial labs offering panels without robust clinical validation
Common Pitfall to Avoid
Do not pursue further workup based on these unvalidated stool markers. This leads to:
- Unnecessary additional testing
- Patient anxiety
- Delayed appropriate management
- Increased healthcare costs
Your Clinical Path Forward
Since your patient has already undergone appropriate evaluation per AGA guidelines 1:
Continue the low-FODMAP diet you've initiated—this has demonstrated efficacy in reducing IBS symptoms, particularly bloating 5, 6
If celiac disease hasn't been definitively excluded, order serum IgA-tTG (not stool tests)
Focus on symptom management for the disorder of gut-brain interaction diagnosis, which is appropriate given the 4-year history and negative workup
Ignore the stool eosinophil and anti-gliadin results—they lack clinical validity for this presentation
The normal calprotectin already tells you there's no significant intestinal inflammation 1, 2, which is the most important information from that stool panel.